Comparative effectiveness and safety of risankizumab vs ustekinumab in patients with Crohn’s disease: a propensity score–matched multicenter retrospective cohort study

Bisher Sawaf, Umberto Battistin, Mohammed Abu-Rumaileh, Kyrillos Mahrous Gerges, Yusuf Hallak, Shahem Abbarh, Elias Batikh, Nwal Hadaki, Muhammed Elhadi, Miguel Regueiro, Mohammad Al-Haddad

Open source

DOI: 10.1093/crocol/otag096
Published: 2026-07
Container: Crohn’s & Colitis 360
Publisher: Oxford University Press (OUP)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/crocol/otag096,
  title = {Comparative effectiveness and safety of risankizumab vs ustekinumab in patients with Crohn’s disease: a propensity score–matched multicenter retrospective cohort study},
  author = {Bisher Sawaf and Umberto Battistin and Mohammed Abu-Rumaileh and Kyrillos Mahrous Gerges and Yusuf Hallak and Shahem Abbarh and Elias Batikh and Nwal Hadaki and Muhammed Elhadi and Miguel Regueiro and Mohammad Al-Haddad},
  year = {2026},
  journal = {Crohn’s \&amp; Colitis 360},
  doi = {10.1093/crocol/otag096},
  url = {https://doi.org/10.1093/crocol/otag096}
}

RIS

TY  - JOUR
TI  - Comparative effectiveness and safety of risankizumab vs ustekinumab in patients with Crohn’s disease: a propensity score–matched multicenter retrospective cohort study
AU  - Bisher Sawaf
AU  - Umberto Battistin
AU  - Mohammed Abu-Rumaileh
AU  - Kyrillos Mahrous Gerges
AU  - Yusuf Hallak
AU  - Shahem Abbarh
AU  - Elias Batikh
AU  - Nwal Hadaki
AU  - Muhammed Elhadi
AU  - Miguel Regueiro
AU  - Mohammad Al-Haddad
PY  - 2026
JO  - Crohn’s &amp; Colitis 360
DO  - 10.1093/crocol/otag096
UR  - https://doi.org/10.1093/crocol/otag096
ER  -

APA

Sawaf, B., Battistin, U., Abu-Rumaileh, M., Gerges, K. M., Hallak, Y., Abbarh, S., Batikh, E., Hadaki, N., Elhadi, M., Regueiro, M., & Al-Haddad, M. (2026). Comparative effectiveness and safety of risankizumab vs ustekinumab in patients with Crohn’s disease: a propensity score–matched multicenter retrospective cohort study. Crohn’s & Colitis 360. https://doi.org/10.1093/crocol/otag096

Source records

crossref · retrieved 2026-09-24T23:27:58.817Z